Funding drought pinches life sciences firms

Back to TopCommentsE-mailPrintBookmark and Share

FAST BioMedical thought it was on to something big—a new kidney test for hospital patients with a potential market of $1 billion.

But last year, FAST stumbled onto an even bigger opportunity—a breakthrough test relevant for virtually all major-surgery patients and most critical-care patients. That market could be several billion dollars.

muldoon-joe-mug Muldoon

That gives FAST CEO Joe Muldoon hope that his company can raise as much as $25 million in venture capital this year and next—even though life sciences companies like his are out of favor with investors.

“We couldn’t have timed this worse from a capital markets perspective,” Muldoon said. “The bar has gotten so high on life sciences to get funding. It’s almost impossible to describe how much the environment has changed.”

FAST is one of a handful of central Indiana companies that have survived a five-year drought in life sciences funding.

Nationally, venture capital investments into life sciences firms totaled $4.9 billion during the first nine months of 2013, which is down 30 percent from the same period in 2008, according to data from Thomson Reuters and PricewaterhouseCoopers. In Indiana, life sciences firms raised $21 million during the first nine months of the year, far lower than any year since 2003.

rop-life-sciences-011314-15col.jpg Dr. Ruben Sandoval, a FAST BioMedical research consultant, prepares a dose of FAST’s imaging agent. The agent measures blood plasma levels, a promising diagnostic test. (Photo courtesy of FAST BioMedical)

To keep kicking, Indiana’s most promising companies have used a variety of strategies to keep their technologies moving forward.

Companies such as ImmuneWorks and EndGenitor Technologies Inc. found a partner to fund their work. EndGenitor, which is using stem cells to develop new therapies, has been funded by Bloomington-based Cook Group Inc.

ImmuneWorks, which is developing a drug for a rare lung disease, received funding from United Therapeutics Corp. until it finished its Phase 1 clinical trial in late 2012. United then decided to end the relationship to focus on its existing products.

United made an option payment that funded ImmuneWorks through 2013. And now, ImmuneWorks is hitting the road to raise as much as $20 million—or to find a strategic partner—to take its drug through the next stages of testing. ImmuneWorks thinks it can get enough funding to start a Phase 2 clinical trial in the third quarter.

ImmuneWorks CEO Wade Lange is heartened by the fact that more than 40 percent of all initial public offerings in 2013 were life sciences companies—meaning investors who have backed the sector before now have more cash in their pockets.

“Certainly the attitude is better, now, more positive than it was a couple years ago,” Lange said. He said he’s scheduled to talk to some venture capitalists at the JP Morgan Healthcare Conference in San Francisco later this month.

West Lafayette-based Endocyte has also turned to a partner for funding, even after it raised more than $90 million in venture capital and another $145 million through public stock offerings.

New-Jersey-based drug giant Merck & Co. Inc. spent $58 million last year to get Endocyte’s ovarian cancer drug vintafolide ready for launch. Company officials expect to receive a decision on the drug from European regulators this month, with a launch possible before year’s end.

Other companies, such as SonarMed Inc. and Nico Neuro Corp., have made it far enough to put products on the market, bringing in some revenue. But both companies are also still raising investment capital to help them build up their commercial teams and keep improving their technology.

“The environment remains challenging and for the foreseeable future looks like it will. It’s really the survival of only the very fittest and heartiest souls,” said David Johnson, CEO of BioCrossroads, an Indianapolis-based life sciences development group, which has invested in FAST BioMedical, ImmuneWorks and SonarMed.

It is taking far longer than entrepreneurs and investors anticipated for life sciences to get a product to market and, even after that, to scale up to the point of profitability, added David Mann, managing director of Carmel-based venture capital firm Spring Mill Venture Partners. It has an investment in SonarMed, which has developed an airway-monitoring system for surgery patients.

“The time lines in venture capital have extended, and we’re no exception,” Mann said.

Those longer time lines might be OK if the potential rewards were also going up. But, if anything, they’ve been going down.

Obamacare and federal sequestration have pinched reimbursement at hospitals, prompting them to scrutinize any new product before agreeing to let its doctors start using it. Private health insurers have been more hesitant about paying high prices for new drugs and devices—unless those products are true breakthroughs that help them save money elsewhere.

As there has been less money searching out deals in the life-sciences space, investors have been able to wait later to invest. That has left early-stage companies—firms that hope to get as far along as FAST, Endocyte and ImmuneWorks—gasping for cash.

“It’s easier to raise $20 million now than it is to raise two,” said Kristin Jones, executive director of the Indiana Health Industry Forum.

Plum position?

FAST has already raised more than $16 million, mostly from a series of local venture firms and angel investors.

That’s enough to get it through its Phase 2 clinical trial, which should be completed by the second quarter.

Assuming that data is positive, Muldoon thinks it will put FAST in a plum position—a company with breakthrough technology, with patents and clinical data in hand.

“It’s been so hard to scrape and fight and raise money and move on. But once you do it, you’re really in some rare air,” he said. “And people notice.”

FAST, which stands for Filtration Assessment and Surveillance Technology, is a firm that has only four full-time employees and eight part-time employees. It outsources everything it can.

FAST’s basic technology consists of two parts: a specially designed drug that is injected into patients, and a machine, called a spectrofloimeter, which can measure the level of FAST’s drug in a patient’s body.

FAST’s system can determine in about three hours how well a patient’s kidneys are clearing its fluid. Similar tests using existing technology typically take days or weeks to generate a result.

The faster turnaround is significant for doctors taking care of hospital patients, who can’t wait weeks to know whether a patient’s kidneys are working, or how well.

Earlier this year, Muldoon was having a beer with a cardiac surgeon, explaining the technology behind his company. The surgeon stopped him mid-sentence.

“Wait a minute,” he said. “You can measure plasma?”

“Yeah,” Muldoon said, “but that’s not important. The important thing is …”

But the surgeon cut him off. Measuring plasma, which is the fluid component of blood, is critical to determining how much blood a patient has. And knowing a patient’s blood volume is key to understanding whether they have the proper amount of fluid in their system.

Medical research from just the past five years has shown that, contrary to previous thinking, over-hydrating a patient can be as detrimental as under-hydrating. Over-hydrated patients might not be getting enough oxygen to their organs or might not have medications get to the intended tissues.

So measuring plasma volume is critical to speeding up recovery times while also reducing complications and readmissions.

That’s good for patients’ health, but also good for hospitals’ finances. That’s because the federal Medicare program and some private health insurers are increasingly paying hospitals bonuses to keep costs lower while keeping quality higher. One way to do that is to shorten the length of hospital stays by helping patients recover faster.

“It was a grace of God thing,” Muldoon said of the plasma insight. “This is good timing for us.”•


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. I think the poster was being sarcastic and only posting or making fun of what is usually posted on here about anything being built in BR or d'town for that matter.

  2. Great news IRL fans: TURBO the IMS sanctioned movie about slugs running the Indy 500 has caught the Securities and Exchange Commission because Dreamworks had to take a $132MILLION write down...because the movie was such a flop. See, the Indy/IMS magic soiled another pair of drawers. Bwahahahahahaha! How's CARTOWN doing? HAHAHAHA...Indy is for losers.

  3. So disappointed in WIBC. This is the last straw to lose a good local morning program. I used to be able to rely on WIBC to give me good local information, news, weather and traffic on my 45 minute commute.Two incidents when I needed local, accurate information regarding severe weather were the first signs I could not now rely on WIBC. I work weekend 12 hour nights for a downtown hospital. This past winter when we had the worst snowfall in my 50 years of life, I came home on a Sunday morning, went to sleep (because I was to go back in Sunday night for another 12 hour shift), and woke up around 1 p.m. to a house with no electricity. I keep an old battery powered radio around and turned on WIBC to see what was going on with the winter storm and the roads and the power outage. Sigh. Only policital stuff. Not even a break in to update on the winter storm warning. The second weather incident occurred when I was driving home during a severe thunderstorm a few months ago. I had already gotten a call from my husband that a tornado warning was just southwest of where I had been. I turned to WIBC to find out what direction the storm was headed so I could figure out a route home, only to find Rush on the air, and again, no breaking away from this stupidity to give me information. Thank God for my phone, which gave me the warning that I was driving in an area where a tornado was seen. Thanks for nothing WIBC. Good luck to you, Steve! We need more of you and not the politics of hatred that WIBC wants to shove at us. Good thing I have Satellite radio.

  4. I read the retail roundup article and tried Burritos and Beers tonight. I'm glad I did, for the food was great. Fresh authentic Mexican food. Great seasoning on the carne asada. A must try!!! Thanks for sharing.

  5. John, unfortunately CTRWD wants to put the tank(s) right next to a nature preserve and at the southern entrance to Carmel off of Keystone. Not exactly the kind of message you want to send to residents and visitors (come see our tanks as you enter our city and we build stuff in nature preserves...